HomeBUSINESS
BUSINESS

Kyowa Kirin Logs Higher Earnings on Milestones, Lower R&D Costs
(Feb.9.2018)

Kyowa Hakko Kirin posted higher sales and profits in 2017 as it pulled in increased milestone payments from AstraZeneca for the asthma treatment benralizumab, with lower R&D costs following the termination of its tivantinib program also lending support ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 20.

News Calendar